Table 1.
Descriptive statistics of the study group (N = 169)
| Factor | Mean ± SD or percentage |
|---|---|
| Sex (males) | 30.8% |
| Age (years) | 54.2 ± 11.8 |
| Race (Caucasians) | 88.2% |
| DAS28 score | 3.79 ± 1.61 |
| Hypertension | 53.3% |
| Diabetes | 11.2% |
| Statin use | 12.4% |
| Systolic blood pressure (mm Hg) | 133.3 ± 20.3 |
| Diastolic blood pressure (mm Hg) | 74.9 ± 10.8 |
| HDL (mg/dL) | 46.6 ± 13.9 |
| LDL (mg/dL) | 112.7 ± 33.4 |
| Triglycerides (mg/dL) | 144.6 ± 178.5 |
| Glucose (mg/dL) | 91.2 ± 18.6 |
| Homocysteine (µmol/L) | 10.5 ± 3.4 |
| F2-Isoprostanes (ng/mg Creatinine) | 3.49 ± 3.80 |
| Current corticosteroid use | 54.4% |
| Current methotrexate use | 71.0% |
| Current antimalarial use | 24.9% |
| Current NSAID use | 33.1% |
| Current COX-2 inhibitor use | 30.2% |
| Current leflunomide use | 18.3% |
| Current anti-TNF blocker use | 20.7% |
| Past steroid use | 34.3% |
| Past methotrexate use | 20.1% |
| Past antimalarial use | 13.0% |
| Past NSAID use | 18.9% |
| Past COX-2 inhibitor use | 36.7% |
| Past anti-TNF blocker use | 6.5% |